Algeta to raise $45.5 million to establish US sales for Alpharadin
This article was originally published in Scrip
Executive Summary
Algeta has raised around NOK260 million ($45.5 million) through a private placing of 2 million shares at NOK143.0 each, money that will be used to support commercial operations in the US following an anticipated launch of its lead product in 2013.